Hansa Biopharma: NiceR is in a good position to expand the future market - Redeye

Almost a year after announcing positive high level results Hansa Biopharma provides additional supporting results from the Phase 1 study as well as an insights in the future NiceR strategy initially targeting the acute stages in three chronic autoimmune diseases; myelin oligodendrocyte glycoprotein antibody disease (MOGAD), neuromyelitis optica (NMO) and myasthenia gravis (MG). The next stage is to engage with regulatory authorities to establish the treatment protocols for the next stage that will include diagnosed patients.

Länk till analysen i sin helhet: https://www.redeye.se/research/1042193/hansa-biopharma-nicer-is-in-a-good-position-to-expand-the-future-market?utm_source=finwire&utm_medium=RSS